Eli Lilly Muted As Arthritis Drug Fails Goals In Covid-19 Patients

© Reuters By Dhirendra Tripathi Investing.com – Shares of Eli Lilly (NYSE:) were marginally negative as the company’s announcement that the phase 3 study of a drug for treating rheumatoid arthritis in Covid-19 patients had failed to meet its goals left traders disappointed. Eli’s filing said patients treated with baricitinib were 2.7% less likely than […]

Continue Reading